PUMA Inhibitor Protection of GI Stem Cells During Chemotherapy
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for chemotherapy- and radiotherapy-induced gastrointestinal injury, particularly those caused by irinotecan hydrochloride (CPT-11), are inadequate, leading to severe side effects like diarrhea and long-term dysfunction without an FDA-approved preventive or therapeutic agent.
Innovation Solution
A small-molecule PUMA inhibitor (PUMAi) is administered to inhibit the activity of p53 upregulated modulator of apoptosis (PUMA) in non-cancer cells, specifically targeting LGR5+ stem cells to prevent apoptosis and protect the gastrointestinal tract from injury.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy or radiotherapy is administered to treat cancer, then antitumor activity is improved, but gastrointestinal injury occurs due to apoptosis of non-cancer cells including LGR5+ stem cells
Solution Approach 1:
The patent applies local quality by selectively protecting non-cancer cells (specifically LGR5+ stem cells and Paneth cells) while allowing chemotherapy to continue acting on cancer cells. The PUMA inhibitor is administered to create a localized protective effect in the gastrointestinal tract, preserving stem cell function and enabling tissue regeneration without interfering with the systemic antitumor activity of the chemotherapy agent.
Solution Approach 2:
The PUMA inhibitor serves as an intermediary substance that mediates between the chemotherapy agent and the non-cancer cells. It blocks the apoptotic pathway activated by chemotherapy in healthy gastrointestinal cells, particularly through inhibition of PUMA-mediated apoptosis in LGR5+ stem cells, thereby preventing gastrointestinal injury while allowing the chemotherapy to maintain its cancer-killing effect.
2Ease of operation
If anti-diarrhea medication is administered to alleviate CPT-11-induced diarrhea, then symptom relief is improved, but long-term GI dysfunction is not effectively reduced
Solution Approach 1:
The patent applies preliminary action by administering the PUMA inhibitor before or during chemotherapy treatment to prevent gastrointestinal injury from occurring in the first place. By protecting LGR5+ stem cells and Paneth cells from apoptosis during the chemotherapy regimen, the inhibitor preserves the regenerative capacity of the gastrointestinal tract, thereby preventing long-term dysfunction rather than merely treating symptoms after they develop.
3Object-affected harmful factors
If PUMA inhibitor is administered to protect non-cancer cells from apoptosis, then gastrointestinal injury is reduced, but potential protection of cancer cells may occur
Solution Approach 1:
The patent applies partial action by selectively protecting specific non-cancer cell populations (LGR5+ stem cells and Paneth cells) while allowing chemotherapy to continue killing cancer cells. The PUMA inhibitor is administered at doses and timepoints that provide sufficient protection to gastrointestinal stem cells without creating excessive protection that would interfere with chemotherapy-induced cancer cell death. This selective partial protection maintains chemotherapy efficacy while preventing gastrointestinal toxicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The PUMAi effectively reduces chemotherapy-induced gastrointestinal damage by preserving stem cells and maintaining genome integrity, while not compromising the antitumor activity of chemotherapy.
Implementation Method 1
administration of the compound inhibits activity of p53 upregulated modulator of apoptosis (PUMA) in at least a non-cancer cell, thereby preventing apoptosis of the non-cancer cell induced by the chemotherapy or radiotherapy
Data Source
Figure 1A~1C
Figure 1D~1F
Figure 2A~2C
AI summary
Provided herein are compositions and methods for preventing or treating gastrointestinal injury induced by chemotherapy or radiotherapy.